RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 45 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 45

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院GuangzhouHospital page
  2. Study siteAffiliated Hospital of Hebei University河北大学附属医院ShijiazhuangHospital page
  3. Study siteAnhui Chest Hospital安徽省胸科医院HefeiHospital page
  4. Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
  5. Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
  6. Study siteCancer Hospital, Shandong First Medical University山东省肿瘤医院JinanHospital page
  7. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  8. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  9. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  10. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  11. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  12. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  13. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  14. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  15. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  16. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  17. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  18. Study siteFujian Provincial Hospital福建省立医院FuzhouHospital page
  19. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  20. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  21. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  22. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  23. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  24. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  25. Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
  26. Study siteLinyi People's Hospital临沂市人民医院LinyiHospital page
  27. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  28. Study siteNantong Tumor Hospital南通市肿瘤医院NantongHospital page
  29. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  30. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  31. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  32. Study siteShantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page
  33. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  34. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  35. Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page
  36. Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
  37. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  38. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  39. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  40. Study siteWeifang People's Hospital潍坊市人民医院WeifangHospital page
  41. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  42. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  43. Study siteXiangyang Central Hospital襄阳市中心医院XiangyangHospital page
  44. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  45. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05920356, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 100 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing

    Inclusion criterion 1

  3. Prior therapy with a KRAS G12C inhibitor

    Exclusion criterion 6

  4. Eastern Cooperative Oncology Group (ECOG) ≤ 1

    Inclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05920356, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing
  • No history of systemic anticancer therapy in metastatic/non-curable settings
  • Eastern Cooperative Oncology Group (ECOG) ≤ 1

Exclusion Criteria:

  • Mixed histology NSCLC with either small-cell or large-cell neuroendocrine cell component or predominant squamous cell histology
  • Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved as a front-line therapy
  • Symptomatic (treated or untreated) brain metastases
  • Gastrointestinal (GI) tract disease causing the inability to take oral medication
  • Myocardial infarction within 6 months of randomization, unstable arrhythmias, or unstable angina
  • Prior therapy with a KRAS G12C inhibitor

Quoted from ClinicalTrials.gov, NCT05920356, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05920356, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05920356